ANDS took a beating on Monday, trading down over 44% after the company announced that it was suspending dosing of its hepatitis C treatment. The company, which is jointly developing the treatment with NVS, said that it makes sense to suspend the trial and analyze recently obtained data. Volume was extremely heavy on Monday, with over 8 million shares of the stock changing hands, compared to a normal daily average volume of just over 400k shares. The stock set a new 52 week low of $2.98 on Monday before bouncing back slightly and closing at $3.69.
Sorry, the comment form is closed at this time.